{"preliminary_commentary":{"by_channel":{"x_thread":7,"youtube":4,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05329766\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["domvanalimab","zimberelimab"],["quemliclustat","zimberelimab"]],"indication":"advanced gastric, gastroesophageal junction or esophageal cancer","name":"EDGE-Gastric","nct_id":"NCT05329766","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=edge-gastric-nct05329766. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EDGE-Gastric","arms":[{"description":"Domvanalimab and zimberelimab once every 4 weeks (Q4W) in addition to FOLFOX chemotherapy by intravenous (IV) infusion once every 2 weeks (Q2W)","label":"A1: First Line - Treatment Naïve Participants","type":"EXPERIMENTAL"},{"description":"Zimberelimab Q4W in addition to chemotherapy with FOLFOX administered by IV infusion Q2W","label":"A2: First Line - Treatment Naïve Participants","type":"EXPERIMENTAL"},{"description":"Non-randomized A3 safety run-in cohort: Domvanalimab and zimberelimab co-administered Q4W via IV infusion over 60 minutes in addition to FOLFOX chemotherapy via IV infusion Q2W.\n\nAfter completion of A3 safety run-in cohort, participants are randomized to the A3 arm. Domvanalimab and zimberelimab co-administered Q4W via IV infusion over 30 minutes, in addition to FOLFOX chemotherapy via IV infusion Q2W","label":"A3 First Line - Treatment Naïve Participants","type":"EXPERIMENTAL"},{"description":"Zimberelimab administered Q4W via IV infusion over 30 minutes, in addition to FOLFOX chemotherapy via IV infusion Q2W","label":"A4 First Line - Treatment Naïve Participants","type":"EXPERIMENTAL"},{"description":"Domvanalimab and zimberelimab administered once every three weeks (Q3W) by IV infusion","label":"B1: Second Line or greater Checkpoint Inhibitor Naïve Participants","type":"EXPERIMENTAL"},{"description":"Quemliclustat Q2W and zimberelimab Q4W administered by IV infusion","label":"B2: Second Line or greater Checkpoint Inhibitor Naïve Participants","type":"EXPERIMENTAL"},{"description":"Domvanalimab and zimberelimab Q3W administered by IV infusion","label":"Cohort C1: Second Line or greater - Checkpoint Inhibitor Experienced Participants","type":"EXPERIMENTAL"}],"collaborators":["Gilead Sciences"],"completion_date":{"date":"2026-09-07","type":"ACTUAL"},"conditions":["Gastrointestinal Tract Malignancies"],"enrollment":{"count":332,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Domvanalimab","otherNames":[],"type":"DRUG"},{"name":"Quemliclustat","otherNames":[],"type":"DRUG"},{"name":"Zimberelimab","otherNames":[],"type":"DRUG"},{"name":"Fluorouracil","otherNames":[],"type":"DRUG"},{"name":"Leucovorin","otherNames":[],"type":"DRUG"},{"name":"Oxaliplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-26","lead_sponsor":"Arcus Biosciences, Inc.","official_title":"A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-09-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants with Adverse Events (AEs)","timeFrame":"Up to 18 months"},{"measure":"Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1","timeFrame":"Up to 18 months"}],"references":[{"citation":"Janjigian YY, Oh DY, Pelster M, Wainberg ZA, Prusty S, Nelson S, DuPage A, Thompson A, Koralek DO, Sison EAR, Rha SY. Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial. Nat Med. 2025 Dec;31(12):4274-4280. doi: 10.1038/s41591-025-04022-w. Epub 2025 Oct 18.","pmid":"41109921","type":"DERIVED"}],"start_date":{"date":"2022-06-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","url":"https://clinicaltrials.gov/study/NCT05329766"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/edge-gastric-nct05329766"}